BioSpace News Archive

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, announced that the Company will present at the MoneyShow June Virtual Event on Wednesday, June 10, 2020 at 12:50 p.m. EDT. Mr. Rodney Varner, Genprex’s Chairman and Chief Executive Officer, will deliver an overview of the Company

New research from Mass General Cancer Center, published in the June 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network, found 40.2% of hospitalized patients with advanced, incurable cancer were functionally impaired at the time of admission,

Omega Bio -tek, Inc. announces the launch of the Mag-Bind® Viral RNA Xpress Kit for the rapid and reliable isolation of Viral RNA from nasopharyngeal (NP) swab specimens that are dry or in viral transport media (VTM). The new kit aims to combat the shortage of RNA purification kits, which is used in the first steps of COVID-19 testing

-- In post-treatment muscle biopsies, clinical trial participants in the high-dose cohort showed a dose-dependent increase in transduction and expression when compared with the low-dose cohort, with a mean of 72% beta-sarcoglycan (beta-SG) positive fibers, as measured by immunohistochemistry (IHC), substantially exceeding the pre-defined 50% measure for success -- -- A mean signal intensity of 73% in the high-dose group was observed compared to normal control -- -- A mean beta-sarcoglycan

EpiVax, Inc. (“EpiVax”) a Rhode Island -based company and recognized leader in the field of immunogenicity assessment today announced it has licensed its advanced in silico toolkit for biologics immunogenicity screening, ISPRI, to AbCellera Biologics Inc. (“AbCellera”).

- More than 176 million lives in the U.S. now covered by payers/managed care/insurance plans within months of FDA approval of VALTOCO, the first and only nasal spray treatment of seizure clusters in patients 6 years of age and older - Neurelis’ patient assistance program supports eligible patients who have no health insurance - Co-pay program for VALTOCO helps commercial patients lower their out-of-pocket costs to as low as $20

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced a change in the format and location of its 2020 Annual Meeting of Shareholders. In light of the continued public health concerns regarding the COVID-19 pandemic, and to protect the health of our shareholders, employees and other attendees, the Annual Meeting will be held

Precision Spine ® Announces the Worldwide Launch of the Reform ® Ti Modular Pedicle Screw System for Surgeons Seeking Increased Flexibility, Versatility, and Visibility in Degenerative and Trauma Procedures PARSIPPANY, N.J.--( BUSINESS WIRE )-- Precision Spine, Inc., a medical device company dedicated to Made-in-the-USA manufacturing, has launched worldwide the Reform ® Ti Modular Pedicle Screw System, which provides surgeons with the increased flexibi

Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, today announced the appointment of Jason O’Neill as chief executive officer, effective June 1, 2020. O’Neill brings extensive pharmaceutical leadership experience to Dendreon, with prominent roles in the are

Rite Aid named top traditional drug store chain in US for removing harmful chemicals in products sold